Matisse Pharmaceuticals
Geleen
About Matisse Pharmaceuticals
Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with fulminant inflammation such as sepsis. The most advanced product in development is the heparin fraction M6229 for the treatment of severe sepsis and septic shock.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $6.0M
- Last round: Series Unknown (Jan 2024)
- Website: matisse-pharma.com
- Phone: +31 (0)88 2554 070
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/matisse-pharmaceuticals-28384 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.